The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …

Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Background Homologous recombination deficiency (HRD) is a phenotype that is
characterized by the inability of a cell to effectively repair DNA double-strand breaks using …

Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA
damage response (DDR) and/or increased replication stress. These alterations promote the …

Background Late-line treatment options for patients with ovarian cancer are few, with the
proportion of patients achieving an overall response typically less than 10%, and median …

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …

Background Poly (ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 …

Fanconi anemia (FA) is a complex genetic disorder characterized by bone marrow failure
(BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer …

Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …